Last mentioned: Jul 21, 2026
Across the most recent 4 stories covering Eli Lilly and Company — 25% positive, 25% negative, 50% neutral sentiment, averaging 6.5/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Off-Label Drug Mandate
The Vida Health nurse insists Davis try generic naltrexone and bupropion (unapproved for sleep apnea) before approving Zepbound, leading him to abandon the process.
Vida Health Assessment
Davis completes blood work, health questionnaires, and multiple video visits with a Vida Health nurse.
Employer Imposes Vida Health Requirement
Before filling the prescription, Davis's employer adds a mandatory program with telehealth company Vida Health to manage obesity drug benefits.
Zepbound Prescription Issued
David Davis receives a prescription for Zepbound from his primary care doctor to treat obstructive sleep apnea.
The suit ensures obesity patients receive the latest efficacy data, as Novo contends Lilly’s ads deny consumers a full picture of treatment options, potentially swaying prescriptions.
Eli Lilly's RET inhibitor Tanstrive hits the Indian market at Rs 2.15 lakh per 14-day course, promising targeted therapy for advanced solid tumors but raising urgent questions about affordability, insurance coverage, and diagnostic capacity in the country's strained healthcare system.
Source: Business News India · Mint
A California man’s employer-mandated use of Vida Health stalled his Zepbound treatment for obstructive sleep apnea, highlighting how telehealth platforms are overriding primary care physicians to reduce obesity drug costs.
Fisher Asset Management LLC increased its position in Eli Lilly and Company by 3.5% during the third quarter, acquiring an additional 150,595 shares. The move brings the firm's total holdings to over 4.45 million shares, signaling continued institutional confidence in the pharmaceutical giant's growth trajectory.
Source: Bbns · The Lincolnian Online
This page surfaces every story mentioning Eli Lilly and Company across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Eli Lilly and Company was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |